<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors></authors><secondary-authors><author><style face="normal" font="default" size="100%">Antman, Elliott</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Enoxaparin Strategy Appears to Reduce Reinfarction Better than Commonly Administered Unfractionated Heparin in ST Elevation Myocardial Infarction</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-20</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment with enoxaparin (a low molecular weight heparin) throughout hospitalization (up to 8 days) significantly reduced the risk of death or nonfatal reinfarction, compared to administration of unfractionated heparin (UFH) for 48 hours in patients with ST-elevation myocardial infarction (STEMI) undergoing fibrinolytic therapy, according to findings from the multicenter multinational ExTRACT-TIMI 25 trial lead by the investigators from the Brigham and Women's Hospital.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>